CAR-T cell therapy development is a complex process that requires standardization.
Mark White
Advertisement
Mark White, PhD, is the associate director of Biopharma Product Marketing at Bio-Rad.
Articles by Mark White
Advertisement
Latest Updated Articles
Assessing the Quality of CAR-T Cells Using ddPCRPublished: March 15th 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
